4DMedical receives U.S. FDA clearance for CT LVAS
Posted: 21 November 2023 Respiratory imaging technology company 4DMedical Limited (ASX:4DX, “4DMedical”, or the “Company”) today announces that it has received clearance for its CT-based ventilation product (CT LVAS™) from the U.S. Food and Drug Administration (FDA). CT…
University of Melbourne unveils six start ups, announces $4.5M investment in company developing psychedelic-assisted therapies
Posted: 17 November 2023 The University of Melbourne has unveiled a cohort of six early-stage startups and announced the first syndicated investment of $4.5 million by the University’s Genesis Pre-Seed Fund and Tin Alley Ventures into a start-up…
Arovella Therapeutics partners with Cell Therapies to develop its ALA-101 manufacturing process for cancer clinical trials
Posted: 17 November 2023 Cell Therapies Pty Ltd is partnering with Arovella Therapeutics (ASX: ALA) to develop the manufacturing process for Arovella’s ALA-101 product candidate to treat cancer patients in upcoming clinical trials. The ALA-101 product incorporates Arovella’s…
Landmark blood test to detect silent, lethal cancer
Posted: 17 November 2023 Research that could lead to the first early detection blood test for pancreatic cancer has received critical funding from PanKind, The Australian Pancreatic Cancer Foundation. Pancreatic cancer is one of Australia’s biggest killers, with poor…
Monash harnesses new frontier in technology to propel promising local drug discoveries
Posted: 17 November 2023 The Monash Institute of Pharmaceutical Sciences (MIPS) has unveiled a brand new instrument – the Thermo Scientific™ Orbitrap™ Astral™ Mass Spectrometer (MS) – which will play a key role in enabling the team to efficiently identify…
Monash University joins Uniseed to supercharge innovation success
Posted: 17 November 2023 Monash University has officially joined the Uniseed investment fund in a collaboration designed to enhance innovation opportunities by amplifying the growth of current and future startup and spinout companies. As a result of Monash…
Burnet Institute enters into a Research Licence and Option Agreement for Stellabody® – a biologic and antibody therapeutics platform – with argenx
Posted: 17 November 2023 Burnet Institute has entered into a research licence and option agreement for Burnet Institute’s Stellabody® technology with argenx. The Stellabody® platform Stellabody® is a unique on-target hexamerisation technology that exploits a natural property of…
White Paper offers roadmap to a vibrant Victorian medtech sector
Posted: 17 November 2023 The Victorian Medtech Skills and Devices Hub (VMH) has released a White Paper identifying the education and training needed to accelerate the growth of Victoria’s vibrant medtech industry. An initiative of the Victorian Government’s Australian Medtech…
Monash engineers make discovery that gives babies with hearing impairment new hope
Posted: 17 November 2023 Monash University Electrical and Computer Systems Engineering and Bionics Institute research teams have used cutting edge light technology invisible to the human eye to non-invasively image brains to help diagnose hearing impairments in infants and prescribe…
First Patient Dosed in Phase III ProstACT GLOBAL Study of Antibody-based Prostate Cancer Therapy Candidate, TLX591
Posted: 14 November 2023 Telix today announces that the first patient has been dosed in the Company’s Phase III ProstACT GLOBAL study of its investigational prostate-specific membrane antigen (PSMA) targeting radio-antibody drug conjugate (rADC) therapy, TLX591 (177Lu-rosopatamab tetraxetan).…
Neuren completes Phelan-McDermid syndrome Phase 2 trial
Posted: 14 November 2023 Neuren Pharmaceuticals (ASX: NEU) today announced that all study visits are complete in its Phase 2 clinical trial of NNZ-2591 in Phelan-McDermid syndrome (PMS). Top-line results from the trial are expected to be available…
Neuren receives Australian Growth Company of the Year Award
Posted: 14 November 2023 Neuren Pharmaceuticals (ASX: NEU) has been presented with the 2023 Australian Growth Company of the Year Award for Health and Life Sciences. Neuren CEO Jon Pilcher commented: “We were very pleased to be recognized…
